Demographic and clinical data of all participants (n=202)
| Variables | n (%) |
| Male | 110 (54.5) |
| Marital status | |
| Single | 164 (81.2) |
| Married or cohabited | 32 (15.8) |
| Divorced or widowed | 6 (3.0) |
| Occupation | |
| Employee | 96 (47.5) |
| Student | 59 (29.2) |
| Business owner | 19 (9.4) |
| Unemployed | 28 (13.9) |
| Underlying medical diseases | 20 (9.9) |
| Diagnosis | |
| Depressive disorder | 97 (48.0) |
| Anxiety disorder | 53 (26.2) |
| Schizophrenia | 31 (15.3) |
| Bipolar disorder | 21 (10.4) |
| History of electroconvulsive therapy | 6 (3.0) |
| Current smoking | 33 (16.3) |
| Current alcohol use | 65 (32.2) |
| Any substance use | 77 (38.1) |
| Antidepressant use | 164 (81.2) |
| Antipsychotic agent use | 66 (32.7) |
| Conventional antipsychotic agent | 14 (6.9) |
| Atypical antipsychotic agent | 56 (27.7) |
| Mood stabiliser use | 26 (12.9) |
| Benzodiazepines use | 89 (44.1) |
| Anticholinergic use | 22 (10.9) |
| Medical drug use | 17 (8.4) |
| Mean (SD) or median [IQR] | |
| Age, years | 30.2 (9.0) |
| Education (years) | 16.0 (2.9) |
| BMI (kg/m2) | 24.3 (4.8) |
| Illness duration (years) | 3 [1, 6] |
| BPRS scores | 26.6 (7.3) |
| Quality of life scores | 85.4 (11.8) |
| Antipsychotic dosage, mg (n=66) chlorpromazine equivalence | 175.0 [78.8, 401.3] |
| Antidepressant dosage, mg (n=164) fluoxetine equivalence | 20.0 [20.0, 40.0] |
| Benzodiazepine dosage, mg (n=89) lorazepam equivalence | 1.0 [0.5, 2.0] |
BMI, body mass index; BPRS, Brief Psychiatric Rating Scale; IQR, interquartile range; SD, standard deviation.